Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

2022/02/16 by L. Gianni, Luca Gianni, C.S. Huang +35 · 2 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Breast Cancer Treatment Studies #Cancer Immunotherapy and Biomarkers #HER2/EGFR in Cancer Research

paper · pdf · doi:10.1016/j.annonc.2022.02.004

openalex publication_date 2022/02/16 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Citations

• Pembrolizumab for Early Triple-Negative Breast Cancer

Cited by

• Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
• Triple-Negative Breast Cancer: Molecular Subtypes, Therapeutic Challenges, and Emerging Strategies—A Systematic Review